Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms

Journal of Clinical Psychiatry

Volumn 57, Issue 7, 1996, Pages 287-291

  Sramek, John J ^a   Tansman, Mara ^a   Suri, Aswinder ^a   Hornig Rohan, Mädy ^b   Amsterdam, Jay D ^b   Stahl, Stephen M ^c   Weisler, Richard H ^d   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BUSPIRONE; CHLORAL HYDRATE; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; FLUOXETINE; LORAZEPAM; PLACEBO;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SWEATING; TABLET; TRANQUILIZING ACTIVITY; VERTIGO;

ADULT; ANXIETY DISORDERS; BUSPIRONE; COMORBIDITY; DEPRESSION; DIZZINESS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NAUSEA; PLACEBOS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SLEEP; SWEATING; TREATMENT OUTCOME;

EID: 0029894030     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993;54(5, suppl):8-16
2. Stavrakaki C, Vargo B. The relationship of anxiety and depression: a review of the literature. Br J Psychiatry 1986;149:7-16
3. Degruy F. Management of mixed anxiety and depression. Am Fam Physician 1994;49:860-866
4. Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993;54(1, suppl):20-23
5. Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993;54(1, suppl):33-38
6. Stahl SM. Phenomenology of anxiety disorders: clinical heterogeneity and comorbidity. In: Westerberg HGM, Murphy DL, DenBoer JA, eds. Advances in the Neurobiology of Anxiety Disorders. Chichester, England: John Wiley & Sons. In press
7. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry 1982;43(12, sec 2):87-91
8. Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982;43(12, sec 2):103-108
9. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43(12, sec 2):81-86
10. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 1991;105: 428-432
11. Gammans RE, Stringfellow JC, Hvizdos AJ, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
15. Covi L, Lipman R, McNair DM, et al. Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol 1979;3:521-533
16. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222
17. Hamilton M. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:179-192
18. Keppel Hesselink JM. Promising anxiolytics? a new class of drugs: the azapirones. In: Stahl SM, Gastpar M, Keppel Hesselink JM, et al, eds. Serotonin IA Receptors in Depression and Anxiety. New York, NY: Raven Press; 1992:171-183
19. Cutler NR, Sramek JJ, Keppel Hesselink JM, et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 1993;13:429-437
20. BuSpar. Physician's Desk Reference. 48th ed. Montvale, NJ: Medical Economics; 1994:1384-1386
21. Harvey SC. Hypnotics and sedatives. In: Gilman AG, Goodman LS, Rall TW, et al, eds. The Pharmacological Basis of Therapeutics. 7th ed. New York, NY: McMillan; 1985:319-371
22. Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquilizers. Pharmacol Ther 1988;36:173-188
23. Ryan HW, Merrill FB, Scott GE, et al. Increase in suicidal thoughts and tendencies. JAMA 1968;203:135-137
24. Hall RCW, Joffe JR. Aberrant response to diazepam: a new syndrome. Am J Psychiatry 1972;129:738-742
25. Gundlach R, Englehardt DM, Hankoff L, et al. A double-blind outpatient study of diazepam (Valium) and placebo. Psychopharmacologia 1966;9:81-92
26. Sramek JJ, Cutler NR, Costa JF, et al. Depression in the course of treatment of generalized anxiety disorder with lorazepam, ipsapirone, and placebo: results from a multicenter trial. Depression 1993;1:172-176
27. 1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog Neuropsychopharmacol Biol Psychiatry 1993;17:87-104
28. 2 receptor-mediated behavior by continuous gepirone treatment. Life Sci 1991;49:1777-1785
29. 1A agonists uncouple noradrenergic somatodendritic impulse flow and terminal release. Brain Res Bull 1991; 27(5):693-696
30. Kostowski W, Dyr W, Krzascik P, et al. 5-Hydroxytryptamine 1A receptor agonists in animal models of depression and anxiety. Pharmacol Toxicol 1992;71(1):24-30
31. Rickels K, Amsterdam JD, Clary C, et al. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-38
32. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990;51(9, suppl):55-61
33. Heller AH, Beneke M, Kuemmel B, et al. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 1990;26:219-222
34. Dompert W, Glaser T, Traber J. 3H-TVX0 7821: identification of 5-HT binding sites as target for the novel putative anxiolytic TVXO 7821. Naunyn Schmiedebergs Arch Pharmacol 1985;328:467-470
35. Stanton HC, Taylor DP, Riblet LA. Buspirone: an anxioselective drug with dopaminergic action. In: Chronister RB, DeFrance JA, eds. The Neurobiology of the Nucleus Accumbens. Brunswick, Me: Haer Institute; 1981
36. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991;69:149-156
37. Riskind JH, Beck AT, Brown G, et al. Taking the measure of anxiety and depression: validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987;175:474-479
38. Montgomery SA, Åsberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389